EPISODE · Oct 10, 2019 · 31 MIN
The Role of Immune Checkpoint Inhibitors in Bladder Cancer
from AUAUniversity · host American Urological Association
Co-Host: Robert Svatek, MD At the conclusion of these activities, participants will be able to: 1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer. 2. Describe the mechanism of action of immunotherapy regimens. 3. Identify and manage the adverse events related to these agents. CME Available: auau.auanet.org/node/26071 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
What this episode covers
Co-Host: Robert Svatek, MD At the conclusion of these activities, participants will be able to: 1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer. 2. Describe the mechanism of action of immunotherapy regimens. 3. Identify and manage the adverse events related to these agents. CME Available: auau.auanet.org/node/26071 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma
NOW PLAYING
The Role of Immune Checkpoint Inhibitors in Bladder Cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.